Cargando…
Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is common in severe coronavirus disease 2019 (COVID-19) and worsens the prognosis. Sildenafil, a phosphodiesterase-5 inhibitor, is approved for PAH treatment but little is known about its efficacy in cases of severe COVID-19 with PAH. This study aimed to investi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223625/ https://www.ncbi.nlm.nih.gov/pubmed/37243243 http://dx.doi.org/10.3390/v15051157 |
_version_ | 1785049986465005568 |
---|---|
author | Oliynyk, Oleksandr Valentynovych Rorat, Marta Strepetova, Olena Vadymivna Dubrov, Serhij Oleksandrovych Guryanov, Vitaliy Grygorovych Oliynyk, Yanina Volodymyrivna Kulivets, Oleksii Serhijovych Ślifirczyk, Anna Barg, Wojciech |
author_facet | Oliynyk, Oleksandr Valentynovych Rorat, Marta Strepetova, Olena Vadymivna Dubrov, Serhij Oleksandrovych Guryanov, Vitaliy Grygorovych Oliynyk, Yanina Volodymyrivna Kulivets, Oleksii Serhijovych Ślifirczyk, Anna Barg, Wojciech |
author_sort | Oliynyk, Oleksandr Valentynovych |
collection | PubMed |
description | Pulmonary arterial hypertension (PAH) is common in severe coronavirus disease 2019 (COVID-19) and worsens the prognosis. Sildenafil, a phosphodiesterase-5 inhibitor, is approved for PAH treatment but little is known about its efficacy in cases of severe COVID-19 with PAH. This study aimed to investigate the clinical efficacy of sildenafil in patients with severe COVID-19 and PAH. Intensive care unit (ICU) patients were randomly assigned to receive sildenafil or a placebo, with 75 participants in each group. Sildenafil was administered orally at 0.25 mg/kg t.i.d. for one week in a placebo-controlled, double-blind manner as an add-on therapy alongside the patient’s routine treatment. The primary endpoint was one-week mortality, and the secondary endpoints were the one-week intubation rate and duration of ICU stay. The mortality rate was 4% vs. 13.3% (p = 0.078), the intubation rate was 8% and 18.7% (p = 0.09), and the length of ICU stay was 15 vs. 19 days (p < 0.001) for the sildenafil and placebo groups, respectively. If adjusted for PAH, sildenafil treatment significantly reduced mortality and intubation risks: OR = 0.21 (95% CI: 0.05–0.89) and OR = 0.26 (95% CI: 0.08–0.86), respectively. Sildenafil demonstrated some clinical efficacy in patients with severe COVID-19 and PAH and should be considered as an add-on therapy in these patients. |
format | Online Article Text |
id | pubmed-10223625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102236252023-05-28 Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension Oliynyk, Oleksandr Valentynovych Rorat, Marta Strepetova, Olena Vadymivna Dubrov, Serhij Oleksandrovych Guryanov, Vitaliy Grygorovych Oliynyk, Yanina Volodymyrivna Kulivets, Oleksii Serhijovych Ślifirczyk, Anna Barg, Wojciech Viruses Article Pulmonary arterial hypertension (PAH) is common in severe coronavirus disease 2019 (COVID-19) and worsens the prognosis. Sildenafil, a phosphodiesterase-5 inhibitor, is approved for PAH treatment but little is known about its efficacy in cases of severe COVID-19 with PAH. This study aimed to investigate the clinical efficacy of sildenafil in patients with severe COVID-19 and PAH. Intensive care unit (ICU) patients were randomly assigned to receive sildenafil or a placebo, with 75 participants in each group. Sildenafil was administered orally at 0.25 mg/kg t.i.d. for one week in a placebo-controlled, double-blind manner as an add-on therapy alongside the patient’s routine treatment. The primary endpoint was one-week mortality, and the secondary endpoints were the one-week intubation rate and duration of ICU stay. The mortality rate was 4% vs. 13.3% (p = 0.078), the intubation rate was 8% and 18.7% (p = 0.09), and the length of ICU stay was 15 vs. 19 days (p < 0.001) for the sildenafil and placebo groups, respectively. If adjusted for PAH, sildenafil treatment significantly reduced mortality and intubation risks: OR = 0.21 (95% CI: 0.05–0.89) and OR = 0.26 (95% CI: 0.08–0.86), respectively. Sildenafil demonstrated some clinical efficacy in patients with severe COVID-19 and PAH and should be considered as an add-on therapy in these patients. MDPI 2023-05-11 /pmc/articles/PMC10223625/ /pubmed/37243243 http://dx.doi.org/10.3390/v15051157 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Oliynyk, Oleksandr Valentynovych Rorat, Marta Strepetova, Olena Vadymivna Dubrov, Serhij Oleksandrovych Guryanov, Vitaliy Grygorovych Oliynyk, Yanina Volodymyrivna Kulivets, Oleksii Serhijovych Ślifirczyk, Anna Barg, Wojciech Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension |
title | Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension |
title_full | Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension |
title_fullStr | Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension |
title_full_unstemmed | Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension |
title_short | Efficacy of Sildenafil in Patients with Severe COVID-19 and Pulmonary Arterial Hypertension |
title_sort | efficacy of sildenafil in patients with severe covid-19 and pulmonary arterial hypertension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223625/ https://www.ncbi.nlm.nih.gov/pubmed/37243243 http://dx.doi.org/10.3390/v15051157 |
work_keys_str_mv | AT oliynykoleksandrvalentynovych efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT roratmarta efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT strepetovaolenavadymivna efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT dubrovserhijoleksandrovych efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT guryanovvitaliygrygorovych efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT oliynykyaninavolodymyrivna efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT kulivetsoleksiiserhijovych efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT slifirczykanna efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension AT bargwojciech efficacyofsildenafilinpatientswithseverecovid19andpulmonaryarterialhypertension |